ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
Medicine
◽
10.1097/md.0000000000023455
◽
2020
◽
Vol 99
(49)
◽
pp. e23455
Author(s):
Si-Yeon Song
◽
Su-Jeong Ha
◽
Ji-Hye Park
◽
So-Jung Park
◽
Seong Hoon Shin
◽
...
Keyword(s):
Combination Therapy
◽
Locally Advanced
◽
Egfr Mutations
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
◽
Metastatic Nsclc
◽
Nsclc Patients
Download Full-text
Related Documents
Cited By
References
A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations: Erratum
Medicine
◽
10.1097/md.0000000000028585
◽
2022
◽
Vol 101
(2)
◽
pp. e28585
Keyword(s):
Combination Therapy
◽
Locally Advanced
◽
Egfr Mutations
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
◽
Metastatic Nsclc
◽
Nsclc Patients
Download Full-text
19 EGFR mutation rate in TRANSCRIPT: A study to assess the incidence of EGFR mutations in UK NSCLC patients with newly diagnosed locally advanced or metastatic disease. A single arm, open label study
Lung Cancer
◽
10.1016/s0169-5002(14)70020-0
◽
2014
◽
Vol 83
◽
pp. S8
Author(s):
C. Lewanski
◽
I. Hennig
◽
S. Tahir
◽
T. Benepal
◽
S. Skaria
◽
...
Keyword(s):
Mutation Rate
◽
Metastatic Disease
◽
Egfr Mutation
◽
Locally Advanced
◽
Egfr Mutations
◽
Newly Diagnosed
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Nsclc Patients
Download Full-text
An Open-label Study of the Safety and Efficacy of Tag-7 Gene-modified Tumor Cell-based Vaccine in Patients With Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer
Case Medical Research
◽
10.31525/ct1-nct04180774
◽
2019
◽
Author(s):
Keyword(s):
Malignant Melanoma
◽
Tumor Cell
◽
Renal Cell
◽
Cell Cancer
◽
Locally Advanced
◽
Metastatic Malignant Melanoma
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
Download Full-text
An open-label study of the safety and efficacy of triple-combination therapy of melasma in african-american patients
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2003.10.478
◽
2004
◽
Vol 50
(3)
◽
pp. P138
Author(s):
Pearl E Grimes
Keyword(s):
African American
◽
Combination Therapy
◽
Triple Combination
◽
Open Label
◽
Triple Combination Therapy
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
Download Full-text
An open-label study of the safety and efficacy of triple-combination therapy of melasma in African-American patients
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2003.11.028
◽
2004
◽
Vol 50
(3)
◽
pp. P176
Author(s):
Pearl Grimes
Keyword(s):
African American
◽
Combination Therapy
◽
Triple Combination
◽
Open Label
◽
Triple Combination Therapy
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
Download Full-text
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Pulmonology
◽
10.1016/j.pulmoe.2020.08.007
◽
2020
◽
Author(s):
F. Barata
◽
H. Queiroga
◽
E. Teixeira
◽
T. Almodovar
◽
M. Soares
◽
...
Keyword(s):
Phase Ii
◽
First Line
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Activating Mutations
◽
Metastatic Nsclc
◽
Nsclc Patients
Download Full-text
Abstract OT-03-08: A Phase 2, open-label study to evaluate the safety and efficacy of the probody therapeutic (Pb-Tx) CX-2009 in metastatic HR-Positive/HER2-negative breast cancer (mHR+/HER2− BC) and of CX-2009 as monotherapy and in combination therapy with CX-072 in metastatic triple-negative breast cancer (TNBC)
10.1158/1538-7445.sabcs20-ot-03-08
◽
2021
◽
Author(s):
Kathy D. Miller
◽
Leisha A. Emens
◽
Sara Tolaney
◽
Sara A. Hurvitz
◽
Erika Hamilton
◽
...
Keyword(s):
Breast Cancer
◽
Combination Therapy
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 2
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
Download Full-text
An Open‐Label Study of the Safety and Efficacy of Tag‐7 Gene‐Modified Tumor Cells‐Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer
The Oncologist
◽
10.1634/theoncologist.2020-0160
◽
2020
◽
Vol 25
(9)
◽
Author(s):
Aleksei Viktorovich Novik
◽
Anna Borisovna Danilova
◽
Maksim Ivanovich Sluzhev
◽
Tatiana Leonidovna Nehaeva
◽
Sergei Sergeevich Larin
◽
...
Keyword(s):
Malignant Melanoma
◽
Tumor Cells
◽
Renal Cell
◽
Cell Cancer
◽
Locally Advanced
◽
Metastatic Malignant Melanoma
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
Download Full-text
An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis
Case Medical Research
◽
10.31525/ct1-nct03977792
◽
2019
◽
Author(s):
Keyword(s):
Herpes Labialis
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
◽
Recurrent Herpes
◽
Cold Sores
Download Full-text
Faculty Opinions recommendation of Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.725336183.793540487
◽
2017
◽
Author(s):
Lori Ann Birder
Keyword(s):
Overactive Bladder
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Safety And Efficacy
◽
Post Marketing
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close